POZ - XVI International AIDS Conference (2006) : IAC: Encouraging Data on Etravirine (TMC-125) - by Tim Horn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Conference Coverage » XVI International AIDS Conference (2006)

emailrssprint

IAC: Encouraging Data on Etravirine (TMC-125)
by Tim Horn

August 15, 2006 (AIDSmeds)—Researchers at the XVI International AIDS Conference in Toronto have reported 48-week results from a phase II clinical trial of etravirine (TMC-125), Tibotec's experimental non-nucleoside reverse transcriptase inhibitor (NNRTI). The new data, reviewed by Cal Cohen, MD, of the Community Research Initiative of New England in Boston at a poster session on Tuesday, indicate that etravirine may offer long-term effectiveness to patients who have tried and failed other HIV treatments, including currently approved NNRTIs.

The study (TMC125-C223) enrolled 199 HIV-positive patients who had failed regimens containing NNRTIs and protease inhibitors in the past. The study volunteers were randomized to one of two etravirine doses (400mg or 800mg twice-daily) plus an "optimized background regimen" (OBR) consisting of available HIV medications. These patients were compared to an "active control" group, in which patients cobbled together the best possible regimen using approved HIV medications.

By week 48, approximately 39 of the 40 (98%) patients in the active control group had discontinued their selected treatment, mostly due to rebounding viral loads. In both etravirine groups, rebounds in viral load were only seen in 9% of the patients. Patients in the active control group remained on their selected treatment regimen for an average of 18 weeks, compared to an average of time on therapy of 48 weeks in the etravirine groups.

Dr. Cohen's group also reported that 23% of patients in the 400mg etravirine group and 22% of patients in the 800mg etravirine group had viral loads below 50 after 48 weeks of treatment, compared to no patients in the active control group. Approximately 31% of patients in the 400mg etravirine group and 34% of patients in the 800mg etravirine group had viral loads that were at least 1 log below their baseline results, compared to only 8% in the active control group.

Patients with the fewest HIV mutations conferring resistance to current NNRTIs – such as K103N and Y181C - had the most pronounced reductions in viral load. For example, in the 800mg etravirine group, patients with only one NNRTI mutation saw their viral loads reduced by 1.67 log by the end of the study, compared to a 0.54 log reduction in patients with HIV containing three or more NNRTI mutations.

As for CD4 counts (T cell counts), there was a 61 cell increase in the 800mg etravirine group and a 58 cell increase in the 400mg group. In the active control group, there was only a 13 cell increase.

Because most patients in the active control group discontinued their selected treatment relatively early in the trial, a true comparison of the side effects isn't really possible. Looking only at patients in the etravirine groups, approximately 22% experienced diarrhea, 20% experienced some type of rash, 20% experienced injection-site reactions (caused by administration of Fuzeon®), and 20% experienced fever. Other reported side effects, occurring in greater that 10% of patients on an etravrine-containing combination, included fatigue, headache, and insomnia.

These data, Dr. Cohen reported, are encouraging. The results of etravirine's larger phase III clinical trials, which are being conducted to support the anticipated 2007 approval of the drug, are eagerly anticipated.

emailrssprint


[Go to top]

POZ Exclusives

What’s Your Long-term Risk of Transmitting HIV?

'Midsummer Night Drinks' Benefits God’s Love We Deliver

Gay Shamelessness, Beyond the Crystal Meth Crisis

» More

What's That Mean?
(just double-click it!)

NEW! If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:


What You're Talking About

Mouth Full of Problems: A Crisis in HIV Dental Care (24)

Sex Crime (23)

HPV Vaccine for Boys: Public Comments Welcome (18)

Sir Elton John Denied Request to Adopt HIV-Positive Ukrainian Child (13)

HIV-Positive Sailor Sentenced for Consensual, Unprotected Sex (8)

Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ



Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    dave41
    Bethany
    Oklahoma


    Poz_Qt
    Columbus
    Ohio


    Deelight4u
    BROOKLYN
    New York


    jap022964
    el dorado
    Arkansas
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Will decriminalizing injection drug use help end the global HIV epidemic?
Yes
No

Survey
PrEP Course

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.